When to stop immunotherapy for advanced melanoma: the emulated target trialsMathilde Amiot, Raphaël Porcher, Jean‐Philippe Arnault et al.|EClinicalMedicine|2024Cited by 7
Methods of nivolumab administration in advanced melanoma: A comparison of patients’ clinical outcomes treated with flat dose or weight‐adjusted dose, a multicenter observational studyIona Campo Le Brun, Emmanuelle Kempf, Stéphane Dalle et al.|Cancer|2024Cited by 5
The efficacy and safety of first-line metastatic melanoma treatment with ipilimumab + nivolumab vs. nivolumab in a real-world settingBillard Karine, Célèste Lebbé, Laurent Mortier et al.|British Journal of Dermatology|2024Cited by 4
When to stop immunotherapy for advanced melanoma: Emulation of target trials.Mathilde Amiot, Raphaël Porcher, Laurent Mortier et al.|Journal of Clinical Oncology|2024Cited by 1